{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:50:59Z","timestamp":1786121459520,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"DOI":"10.1007\/s40256-026-00818-4","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:37:45Z","timestamp":1786081065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adherence and Healthcare Costs Associated with Single-vs Free-Pill Combination of Perindopril-Based Antihypertensive Medications: An 11-Year Follow-Up, Real-World Evidence"],"prefix":"10.1007","author":[{"given":"Gianluigi","family":"Savarese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4325-4932","authenticated-orcid":false,"given":"Ana-Maria","family":"Vintila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Degli Esposti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Dovizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Magne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Nugnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Veronesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"10258","key":"818_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322.","journal-title":"Lancet"},{"issue":"4","key":"818_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40292-022-00519-4","volume":"29","author":"R Del Pinto","year":"2021","unstructured":"Del Pinto R, Grassi G, Muiesan ML, Borghi C, Carugo S, Cicero AFG, et al. World Hypertension Day 2021 in Italy: results of a nationwide survey. High Blood Press Cardiovasc Prev. 2021;29(4):353\u20139.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"10304","key":"818_CR3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"B Zhou","year":"2021","unstructured":"Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957\u201380.","journal-title":"Lancet"},{"issue":"11","key":"818_CR4","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","volume":"18","author":"B Zhou","year":"2021","unstructured":"Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785\u2013802.","journal-title":"Nat Rev Cardiol"},{"issue":"3 Suppl 2","key":"818_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1524-6175.2003.02463.x","volume":"5","author":"WJ Elliott","year":"2003","unstructured":"Elliott WJ. The economic impact of hypertension. J Clin Hypertens (Greenwich). 2003;5(3 Suppl 2):3\u201313.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"5","key":"818_CR6","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.5114\/aoms.2020.92689","volume":"16","author":"E Wierzejska","year":"2020","unstructured":"Wierzejska E, Giernas B, Lipiak A, Karasiewicz M, Cofta M, Staszewski R. A global perspective on the costs of hypertension: a systematic review. Arch Med Sci. 2020;16(5):1078\u201391.","journal-title":"Arch Med Sci"},{"issue":"1","key":"818_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10198-013-0554-4","volume":"16","author":"FS Mennini","year":"2015","unstructured":"Mennini FS, Marcellusi A, von der Schulenburg JM, Gray A, Levy P, Sciattella P, et al. Cost of poor adherence to anti-hypertensive therapy in five European countries. Eur J Health Econ. 2015;16(1):65\u201372.","journal-title":"Eur J Health Econ"},{"issue":"10","key":"818_CR8","first-page":"3","volume":"15","author":"M Volpe","year":"2014","unstructured":"Volpe M, Degli Esposti L, Romeo F, Trimarco B, Bovenzi FM, Mastromarino V, et al. The role of adherence to drug treatment in the chronic therapy of cardiovascular diseases: intercompany consensus document. G Ital Cardiol. 2014;15(10):3\u201310.","journal-title":"G Ital Cardiol"},{"key":"818_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00100","volume":"8","author":"B Vrijens","year":"2017","unstructured":"Vrijens B, Antoniou S, Burnier M, de la Sierra A, Volpe M. Current situation of medication adherence in hypertension. Front Pharmacol. 2017;8:100.","journal-title":"Front Pharmacol"},{"key":"818_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/CEOR.S15619","volume":"3","author":"L Degli Esposti","year":"2011","unstructured":"Degli Esposti L, Saragoni S, Benemei S, Batacchi P, Geppetti P, Di Bari M, et al. Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients. Clinicoecon Outcomes Res. 2011;3:47\u201354.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"6","key":"818_CR11","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.116.08729","volume":"69","author":"P Gupta","year":"2017","unstructured":"Gupta P, Patel P, Strauch B, Lai FY, Akbarov A, Maresova V, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69(6):1113\u201320.","journal-title":"Hypertension"},{"issue":"1","key":"818_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.medcle.2018.10.026","volume":"153","author":"A Moreno Juste","year":"2019","unstructured":"Moreno Juste A, Gimeno Miguel A, Poblador Plou B, Gonz\u00e1lez Rubio F, Aza Pascual-Salcedo MM, Menditto E, et al. Adherence to treatment of hypertension, hypercholesterolaemia and diabetes in an elderly population of a Spanish cohort. Medicina Cl\u00ednica (English Edition). 2019;153(1):1\u20135.","journal-title":"Medicina Cl\u00ednica (English Edition)"},{"issue":"9","key":"818_CR13","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1080\/03007995.2018.1433648","volume":"34","author":"L Degli Esposti","year":"2018","unstructured":"Degli Esposti L, Perrone V, Veronesi C, Gambera M, Nati G, Perone F, et al. Modifications in drug adherence after switch to fixed-dose combination of perindopril\/amlodipine in clinical practice. Results of a large-scale Italian experience. The amlodipine-perindopril in real settings (AMPERES) study. Curr Med Res Opin. 2018;34(9):1571\u20137.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"818_CR14","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1097\/HJH.0000000000002598","volume":"38","author":"E Campana","year":"2020","unstructured":"Campana E, Cunha V, Glaveckaite S, Gruev I, Lamirault G, Lehmann E, et al. The use of single-pill combinations as first-line treatment for hypertension: translating guidelines into clinical practice. J Hypertens. 2020;38(12):2369\u201377.","journal-title":"J Hypertens"},{"issue":"4","key":"818_CR15","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s12325-023-02451-y","volume":"40","author":"C Borghi","year":"2023","unstructured":"Borghi C, Jayagopal PB, Konradi A, Bortolotto LA, Degli Esposti L, Perrone V, et al. Adherence to triple single-pill combination of perindopril\/indapamide\/amlodipine: findings from real-world analysis in Italy. Adv Ther. 2023;40(4):1765\u201372.","journal-title":"Adv Ther"},{"issue":"38","key":"818_CR16","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024;45(38):3912\u20134018.","journal-title":"Eur Heart J"},{"issue":"6","key":"818_CR17","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334\u201357.","journal-title":"Hypertension"},{"key":"818_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2024.05.033","volume":"126","author":"R Kreutz","year":"2024","unstructured":"Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024;126:1\u201315.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"818_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/HJH.0000000000003570","volume":"42","author":"JR Snyman","year":"2024","unstructured":"Snyman JR, Bortolotto LA, Degli Esposti L, Jayagopal PB, Konradi AO, Perrone V, et al. A real-world analysis of outcomes and healthcare costs of patients on perindopril\/indapamide\/amlodipine single-pill vs. multiple-pill combination in Italy. J Hypertens. 2024;42(1):136\u201342.","journal-title":"J Hypertens"},{"issue":"1","key":"818_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12325-023-02707-7","volume":"41","author":"S Masi","year":"2024","unstructured":"Masi S, Kobalava Z, Veronesi C, Giacomini E, Degli Esposti L, Tsioufis K. A retrospective observational real-word analysis of the adherence, healthcare resource consumption and costs in patients treated with bisoprolol\/perindopril as single-pill or free combination. Adv Ther. 2024;41(1):182\u201397.","journal-title":"Adv Ther"},{"issue":"5","key":"818_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"3","key":"818_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/pds.3935","volume":"25","author":"MJ Bijlsma","year":"2016","unstructured":"Bijlsma MJ, Janssen F, Hak E. Estimating time-varying drug adherence using electronic records: extending the proportion of days covered (PDC) method. Pharmacoepidemiol Drug Saf. 2016;25(3):325\u201332.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"818_CR23","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","volume":"77","author":"G Parati","year":"2021","unstructured":"Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77(2):692\u2013705.","journal-title":"Hypertension"},{"issue":"5","key":"818_CR24","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/jch.13272","volume":"20","author":"LP Du","year":"2018","unstructured":"Du LP, Cheng ZW, Zhang YX, Li Y, Mei D. The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis. J Clin Hypertens (Greenwich). 2018;20(5):902\u20137.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9","key":"818_CR25","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1097\/HJH.0000000000004050","volume":"43","author":"M Pikkemaat","year":"2025","unstructured":"Pikkemaat M, Atkins ER, Rodgers A, Schutte AE. Treating hypertension with single pill combinations: a simple strategy to save costs for the patients and payers. Jhypertension. 2025;43(9):1478\u201384.","journal-title":"Jhypertension."},{"issue":"35","key":"818_CR26","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1093\/eurheartj\/ehab899","volume":"43","author":"G Corrao","year":"2022","unstructured":"Corrao G, Mancia G. Research strategies in treatment of hypertension: value of retrospective real-life data. Eur Heart J. 2022;43(35):3312\u201322.","journal-title":"Eur Heart J"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00818-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00818-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00818-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:37:46Z","timestamp":1786081066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00818-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":26,"alternative-id":["818"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00818-4","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G. Savarese reports receiving grants and personal fees from CSL Vifor, Boehringer Ingelheim, AstraZeneca, Servier, Novartis, Cytokinetics, Pharmacosmos, Medtronic, Bayer; personal fees from Roche, Abbott, Edwards Lifescience, TEVA, Menarini, INTAS, GETZ, Laboratori Guidotti; and grants from Boston Scientific and Merck, all unrelated to the submitted work. A.\u00a0M. Vintila has received speaker fees, consultancy fees, was a member of advisory boards or has appeared on expert panels for: Amgen, Astra Zeneca, Bayer, Berlin Chemie Menarini, Boehringer Ingelheim, Egis, KRKA, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Terapia, Viatris, Vifor Pharma, Zentiva. J. Magne has received consultant fees from Servier. J. Wolf reports consulting fees and honoraria from Servier for lectures\/speaking activities and educational activities. He reports honoraria from Servier for contributions to the study design and result interpretation. He is the immediate past president of the Polish Society of Hypertension. S. Masi has received payments for consultancy, advisory board participation, speaking, and lecturing activities from Servier, which are related to the topic of this study. He also received honoraria from Servier for contributions to the study design and interpretation of results for the current study. L. Degli Esposti, M. Dovizio, M. Nugnes, and C. Veronesi declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"To guarantee patient privacy, an pseudonymized numeric code (patient identifier or ID) was assigned to each subject by the LHUs, in full compliance with the European General Data Protection Regulation (GDPR) 2016\/679. This code permitted electronic linkage across databases, but no patient IDs were provided to the authors. The study was approved by all local ethics committees of participating LHUs. The requirement to collect informed consent was waived, as it was considered unfeasible owing to organisational issues, in accordance with the \u2018Data Privacy Guarantor Authority, General Authorization for personal data treatment for scientific research purposes \u2013 n.9\/2014\u2019 and subsequent updates.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data sets used and analyzed during the current study will be shared on reasonable request to the corresponding author. The machine code and algorithms used for data extraction, processing, and analysis are not publicly available due to institutional policies, data use rules, and privacy issues. However, they can be made available upon reasonable request for academic or non-commercial purposes, in accordance with applicable privacy and data governance regulations.","order":3,"name":"Ethics","label":"Data availability statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An abstract reporting these data was presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe congress (17-20 November 2024, Barcelona), under the following title: \u201cImpact of Single-Pill Combinations and Level of Adherence on Healthcare Costs in Italian Hypertensive Patients Treated with Perindopril-Based Regimens.\u201d","order":4,"name":"Ethics","label":"Previous presentations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"G. Savarese:\u00a0conceptualization and development of the study design, results interpretation, critical review of the first and\u00a0subsequent\u00a0drafts of the manuscript. A.\u00a0M. Vintila:\u00a0conceptualization and development of the study design, results interpretation, critical review of the first and\u00a0subsequent\u00a0drafts of the manuscript. L. Degli Esposti:\u00a0conceptualization,\u00a0contribution to methodological development, oversight and support in the use and interpretation of administrative healthcare database data, and validation of analytical processes and results. M. Dovizio:\u00a0project management,\u00a0coordination\u00a0and supervision of activities across research phases. J. Magne:\u00a0conceptualization and development of the study design, results interpretation, critical review of the first and\u00a0subsequent\u00a0drafts of the manuscript. M. Nugnes:\u00a0project management, coordination of activities across research phases,\u00a0contribution to the preparation of the\u00a0initial\u00a0manuscript draft. C. Veronesi:\u00a0statistical analyses, data curation and management, development and implementation of analytic procedures, methodological refinement through software-based data processing. J. Wolf:\u00a0conceptualization and development of the study design, results interpretation, critical review of the first and\u00a0subsequent\u00a0drafts of the manuscript. S. Masi:\u00a0conceptualization\u00a0and\u00a0development of the study design,\u00a0results\u00a0interpretation,\u00a0critical review of the first and\u00a0subsequent\u00a0drafts\u00a0of the manuscript.\u00a0Jacek Wolf and Stefano Masi contributed equally to this work.","order":5,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}